A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621 a Novel Biologic Targeting CD47 in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.